Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Payables: 2011-2024

Historic Payables for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $8.5 million.

  • Niagen Bioscience's Payables rose 84.59% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.6 million, marking a year-over-year increase of 37.54%. This contributed to the annual value of $8.5 million for FY2024, which is 16.67% down from last year.
  • Latest data reveals that Niagen Bioscience reported Payables of $8.5 million as of FY2024, which was down 16.67% from $10.2 million recorded in FY2023.
  • Niagen Bioscience's 5-year Payables high stood at $10.4 million for FY2021, and its period low was $8.5 million during FY2024.
  • Over the past 3 years, Niagen Bioscience's median Payables value was $9.7 million (recorded in 2022), while the average stood at $9.5 million.
  • As far as peak fluctuations go, Niagen Bioscience's Payables increased by 10.35% in 2021, and later dropped by 16.67% in 2024.
  • Niagen Bioscience's Payables (Yearly) stood at $9.4 million in 2020, then rose by 10.35% to $10.4 million in 2021, then dropped by 7.14% to $9.7 million in 2022, then increased by 5.71% to $10.2 million in 2023, then decreased by 16.67% to $8.5 million in 2024.